Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry

Citations

WEB OF SCIENCE

5

초록

Objectives Compared with dual antiplatelet therapy including aspirin and clopidogrel, triple antiplatelet therapy including cilostazol has a mortality benefit in patients with ST-segment elevation myocardial infarction. However, whether the mortality benefit persists in elderly patients is not clear. Methods From 2007 to 2014, 1278 patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention were retrospectively analyzed. The patients were divided into four groups by age (<75 or >= 75 years; young and elderly, respectively) and antiplatelet strategy ( triple or dual antiplatelet therapy). We compared the mortality rates between the triple and dual antiplatelet therapy groups. Results There were 1052 (male, 85%; mean age, 56.3 +/- 10.4 years) patients in the young group and 241 (male, 52.7%; mean age, 80.3 +/- 4.5 years) patients in the elderly group. In the young and elderly groups, 220 (20.9%) and 28 (12.3%) patients were treated with triple antiplatelet therapy. During a 1-year follow-up period, 80 patients died (4.2% in the young group vs. 15.5% in the elderly group). Kaplan-Meier survival analysis revealed that triple antiplatelet therapy was associated with a lower mortality rate in the young group (log-rank, p = 0.005). Although there were more angiographic high-risk patients in the elderly group, similar mortality rates were reported (log-rank, p = 0.803) without increased bleeding rates (1 vs. 3.6% in the elderly group, p = 0.217). Conclusions Triple antiplatelet therapy might be a better antiplatelet regimen than dual antiplatelet therapy for patients with ST-segment elevation myocardial infarction. Although this benefit was strong in patients aged <75 years, no definite increase in major bleeding was seen for elderly patients (aged >= 75 years).

키워드

Triple antiplatelet therapy might be a better antiplatelet regimen than dual antiplatelet therapy for patients with ST-segment elevation myocardial infarction. Although this benefit was strong in patients aged <75 yearsno definite increase in major bleeding was seen for elderly patients (aged ≥75 years).ELUTING STENT IMPLANTATIONRANDOMIZED-TRIALSADDING CILOSTAZOLTASK-FORCECLOPIDOGRELMETAANALYSISEFFICACYASPIRINSAFETYMECHANISM
제목
Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry
저자
Jang, Ho-JunPark, Sang-DonPark, Hyun WooSuh, JonOh, Pyung ChunMoon, JeonggeunLee, KyounghoonKang, Woong CholKwon, Sung WooKim, Tae-Hoon
DOI
10.1007/s40266-017-0463-9
발행일
2017-06
유형
Article
저널명
Drugs and Aging
34
6
페이지
467 ~ 477